[Paradoxic improvement of glucose intolerance in 8 females using estrogen-progestagen contraceptives containing norgestrel and ethinyl-estradiol]. 1985

P Vexiau, and J P Gautray, and G Lelorier, and N Thibult, and G Cathelineau

Sixty females, aged 20 to 35, received an oral contraceptive pill (Norgestrel 0.5 mg and Ethinyloestradiol 50 micrograms/day) during one year. Group I was formed by 41 normal patients before and after 12 months. Group II was formed by 11 patients, normal before and with impaired oral glucose tolerance after 12 months. Group III was formed by 8 patients with impaired glucose tolerance before treatment and normal oral glucose tolerance after 12 months. All patients were submitted to 3 oral glucose tolerance tests, the first one at the 16th day of the control cycle, the second and the third at the 16th days of the 6th and 12th cycles during treatment. No significative modification of glycemia, insulinemia or weight was noted in group I. In group II the impaired oral glucose tolerance was associated with an increase of weight. In group III the improvement of glucose tolerance was marked by hyperinsulinemia.

UI MeSH Term Description Entries
D009644 Norgestrel A synthetic progestational agent with actions similar to those of PROGESTERONE. This racemic or (+-)-form has about half the potency of the levo form (LEVONORGESTREL). Norgestrel is used as a contraceptive, ovulation inhibitor, and for the control of menstrual disorders and endometriosis. 18,19-Dinorpregn-4-en-20-yn-3-one, 13-ethyl-17-hydroxy-, (17alpha)-(+-)-,DL-Norgestrel,Neogest,Ovrette,Postinor,Wy-3707,DL Norgestrel,Wy 3707,Wy3707
D001786 Blood Glucose Glucose in blood. Blood Sugar,Glucose, Blood,Sugar, Blood
D003277 Contraceptives, Oral, Combined Fixed drug combinations administered orally for contraceptive purposes. Combined Oral Contraceptive,Contraceptive Agents, Female, Combined,Oral Contraceptives, Combined,Combined Oral Contraceptives,Contraceptive, Combined Oral,Contraceptives, Combined Oral,Oral Contraceptive, Combined
D004997 Ethinyl Estradiol A semisynthetic alkylated ESTRADIOL with a 17-alpha-ethinyl substitution. It has high estrogenic potency when administered orally, and is often used as the estrogenic component in ORAL CONTRACEPTIVES. 19-Norpregna-1,3,5(10)-trien-20-yne-3,17-diol, (17alpha)-,Ethynyl Estradiol,Estinyl,Ethinyl Estradiol Hemihydrate,Ethinyl Estradiol, (8 alpha)-Isomer,Ethinyl Estradiol, (8 alpha,17 alpha)-Isomer,Ethinyl Estradiol, (8 alpha,9 beta,13 alpha,14 beta)-Isomer,Ethinyl Estradiol, (9 beta,17 alpha)-Isomer,Ethinyl-Oestradiol Effik,Ethinylestradiol Jenapharm,Ethinyloestradiol,Lynoral,Microfollin,Microfollin Forte,Progynon C,Estradiol, Ethinyl,Estradiol, Ethynyl,Ethinyl Oestradiol Effik,Hemihydrate, Ethinyl Estradiol,Jenapharm, Ethinylestradiol
D005260 Female Females
D005500 Follow-Up Studies Studies in which individuals or populations are followed to assess the outcome of exposures, procedures, or effects of a characteristic, e.g., occurrence of disease. Followup Studies,Follow Up Studies,Follow-Up Study,Followup Study,Studies, Follow-Up,Studies, Followup,Study, Follow-Up,Study, Followup
D005951 Glucose Tolerance Test A test to determine the ability of an individual to maintain HOMEOSTASIS of BLOOD GLUCOSE. It includes measuring blood glucose levels in a fasting state, and at prescribed intervals before and after oral glucose intake (75 or 100 g) or intravenous infusion (0.5 g/kg). Intravenous Glucose Tolerance,Intravenous Glucose Tolerance Test,OGTT,Oral Glucose Tolerance,Oral Glucose Tolerance Test,Glucose Tolerance Tests,Glucose Tolerance, Oral
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D013997 Time Factors Elements of limited time intervals, contributing to particular results or situations. Time Series,Factor, Time,Time Factor

Related Publications

P Vexiau, and J P Gautray, and G Lelorier, and N Thibult, and G Cathelineau
October 1970, Prensa medica argentina,
P Vexiau, and J P Gautray, and G Lelorier, and N Thibult, and G Cathelineau
March 1978, Contraception,
P Vexiau, and J P Gautray, and G Lelorier, and N Thibult, and G Cathelineau
August 1983, Contraception,
P Vexiau, and J P Gautray, and G Lelorier, and N Thibult, and G Cathelineau
January 1985, Acta physiologica et pharmacologica Bulgarica,
P Vexiau, and J P Gautray, and G Lelorier, and N Thibult, and G Cathelineau
October 1998, Presse medicale (Paris, France : 1983),
P Vexiau, and J P Gautray, and G Lelorier, and N Thibult, and G Cathelineau
September 1984, Fertility and sterility,
P Vexiau, and J P Gautray, and G Lelorier, and N Thibult, and G Cathelineau
May 1986, Therapeutische Umschau. Revue therapeutique,
P Vexiau, and J P Gautray, and G Lelorier, and N Thibult, and G Cathelineau
November 1968, La semaine des hopitaux : organe fonde par l'Association d'enseignement medical des hopitaux de Paris,
P Vexiau, and J P Gautray, and G Lelorier, and N Thibult, and G Cathelineau
June 1992, Contraception,
P Vexiau, and J P Gautray, and G Lelorier, and N Thibult, and G Cathelineau
May 1977, Fertility and sterility,
Copied contents to your clipboard!